Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
Basel, 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer... Read more